NTU Theses and Dissertations Repository: 瀏覽

瀏覽的方式：指導教授 Chia-Chi Lin

跳到： 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
或是輸入前幾個字：

顯示 1 到 8 筆資料，總共 8 筆

出版年	標題	作者	系所
2023	呼吸衰竭患者中T型管呼吸和壓力支持通氣作為自主呼吸測試的比較:系統性回顧和統合分析與試驗計劃書 Comparison of T-piece and Pressure Support Ventilation as Spontaneous Breathing Trials in Patient with Respiratory Failure: a Systematic Review and Meta-analysis, Protocol	林庭宇; Ting-Yu Lin	臨床醫學研究所
2024	抗PD-1/PD-L1抗體聯合療法與化學治療，適用順鉑的晚期泌尿道上皮癌患者第一線治療比較: 系統性回顧、網絡後設分析及臨床試驗計畫書 Anti-PD-1/ PD-L1-antibodies-based combination therapy versus chemotherapy as the first-line therapy in cisplatineligible patients with advanced urothelial cancer: A systematic review, network meta-analysis, and the clinical study protocol	張莘芳; Hsin-Fang Chang	臨床醫學研究所
2025	新型治療相比化療治療用在HER2陽性晚期胃癌二線及以上治療系統性文獻回顧、統合分析及臨床試驗方案 Novel Therapy vs. Chemotherapy as the Second-line Therapy and Beyond of HER2-positive Advanced Gastric Cancer: Systematic Review, Meta-analysis, and Clinical Trial Protocol	廖奕如; IJU Liao	臨床醫學研究所
2023	新輔助免疫檢查點抑制劑(抗程序性細胞死亡受體-1/程序性細胞死亡-配體1抗體)聯合化學治療用於可切除非小細胞肺癌：系統性回顧、統合分析及臨床試驗計畫書 Neoadjuvant Immune Checkpoint Inhibitor (Anti-PD-1/PD-L1 Antibodies) Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Systematic Review, Meta-Analysis and Clinical Trial Protocol	簡韶萱; Shao-Hsuan Chien	臨床醫學研究所
2023	標靶治療加化療對於可能可切除的致癌基因驅動型非小細胞肺癌(NSCLC)作為術前輔助療法：系統性回顧、整合分析以及後續之傘形設計、隨機、雙盲、安慰劑對照試驗 Targeted Therapy Plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment for Potentially Resectable Oncogene Driven Non-Small-Cell Lung Cancer (NSCLC): Systemic Review and Meta-Analysis and an Umbrella Design, Double Blind, Randomized, Placebo Controlled Trial	林士森; Shih-Sen Lin	臨床醫學研究所
2023	比較第三代與上一代表皮生長因子接受器抑制劑用在第一線治療轉移性表皮生長因子接受器突變非小細胞肺癌之系統性回顧、統合分析及臨床試驗計畫書 d generation EGFR inhibitors vs. prior generation EGFR inhibitors as the first-line therapy in metastatic EGFR mutant non-small cell lung cancer: A systematic review and meta-analysis as well as a clinical trial protocol	詹巧雯; Chiao-Wen Chan	臨床醫學研究所
2025	第三代酪胺酸激酶抑制劑合併全身治療與單用第三代酪胺酸激酶抑制劑在帶有表皮生長因子受體突變之第IV期非小細胞肺癌第一線治療中的比較：系統性回顧、網絡統合分析與臨床試驗計劃書 Third-generation EGFR TKI plus Systemic Therapy vs. Third-generation EGFR TKI in EGFR-mutant Stage IV Non-small Cell Lung cancer: A Systematic Review, Network Meta-analysis, and Clinical Trial Protocol	陳玟伶; Wen ling Chen	臨床醫學研究所
2025	表皮生長因子受體酪胺酸酶抑制劑產生抗藥性的非小細胞肺癌患者使用免疫治療合併化學治療加上有無抗血管新生抑制劑與單獨化學治療之療效比較：系統性文獻回顧及統合分析 Immunotherapy combined with chemotherapy with or without anti-angiogenic agents versus chemotherapy in patients with EGFR-mutant non-small cell lung cancer after resistance to EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis	賴力蘭; Li-Lan Lai	臨床醫學研究所

顯示 1 到 8 筆資料，總共 8 筆